Eisai Receives "IR Grand Prix Award"

Nov, 14 2018 13:30 JST

Source: Eisai

TOKYO, Nov, 14 2018 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received the "IR Grand Prix Award" at the IR Award 2018 held by the Japan Investor Relations Association (JIRA). This marks the second time that Eisai has received the IR Grand Prix Award following 2006. Including the receipt of Best IR Awards in 2004, 2005, 2009 and 2012, this is the 6th time Eisai has received an IR Award, and Eisai is the first pharmaceutical company to receive two IR Grand Prix Awards.

The IR Award (Committee Chairman: Tetsuo Kitagawa, Professor of International Management, Aoyama Gakuin University Graduate School) is designed to recognize companies which have been highly accredited in the investment community for their understanding and promotion of IR activities, and this year marks the 23rd year since the start of the IR Awards. 299 companies applied for the IR Award 2018, and after surveys and screenings by select committee members, Eisai was the sole company selected for the IR Grand Prix Award this year.

The reasons for Eisai's selection are as follows:
"Eisai is proactively disclosing information and constantly raising the level of disclosure. For many years, top management has been engaged in dialogue with investors, candidly discussing the company's longer-term vision and management issues. Eisai's CFO and IR Department have been enhancing the presentation of balance sheet management and disclosure of non-financial information ahead of other companies. In terms of ESG-related efforts, Eisai not only discloses information but also holds meetings with presentations by outside directors and meetings to explain its integrated report. The company's timeliness and fairness in disclosure is highly regarded, evidenced by its timely disclosure of information that may affect operating performance and prompt holding of briefings on such matters."

Furthermore, in celebration of the 25th year since the establishment of the JIRA, as part of the "JIRA 25th Anniversary Commemorative Award" which seeks to specially recognize companies which have continued IR activities over the long term and have produced outstanding achievements in appropriate information disclosure and constructive dialogue with investors and shareholders, Eisai was selected as both a "Company with Greatest Improvement in IR" and as a "Company with Best Continual Efforts in IR." For further details, please visit the JIRA website: https://www.jira.or.jp/english/.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform

December 18 2018 10:38 JST

Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma

December 17 2018 08:21 JST

GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics

December 12 2018 09:06 JST

Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research

December 06 2018 09:24 JST

Eisai: MOVICOL Launched in Japan

November 29 2018 13:48 JST

Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa

November 28 2018 10:55 JST

Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium

November 27 2018 17:02 JST

Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting

November 23 2018 07:14 JST

Eisai Launches Lenvima (Lenvatinib) in China

November 12 2018 11:51 JST

Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

November 09 2018 08:08 JST

More Press release >>

Latest Press Release

Mitsubishi Corporation has Reached Agreement to Sell its Interests in the Clermont and Ulan Coal Mines in Australia
Dec 18, 2018 18:49 JST

Sharp to Take Part in CES 2019, First Time in 4 Years
Dec 18, 2018 18:37 JST

Toyota 5 Continents Drive Project Following Africa, the Project Moves to its Final Continent--Asia--in 2019 and 2020
Dec 18, 2018 18:05 JST

Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform
Dec 18, 2018 11:38 JST

Hitachi to Strengthen Energy Solutions Business with the Acquisition of ABB's Power Grids Business
Dec 18, 2018 08:25 JST

Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma
Dec 17, 2018 09:21 JST

NEC Takes Top Spot as Worldwide Market Leader in MZA's Global Call Control (PBX-IP PBX) Market Report
Dec 14, 2018 15:40 JST

"docomo Money Transfer" Mobile Remittance Service to Add China and Thailand

Dec 14, 2018 14:34 JST

Hitachi to Transfer Shares in Hitachi Procurement Service to Infosys, Panasonic, and PASONA
Dec 14, 2018 14:10 JST

Mitsubishi Corporation to Participate in Carbon Fiber Reprocessing Business in the UK
Dec 14, 2018 12:53 JST

Mitsubishi Shipbuilding Holds Christening Ceremony for LPG Carrier "LAUREL PRIME"

Dec 14, 2018 11:13 JST

NSITEXE Develops Test Chip with Next-generation Semiconductor IP Core Called a DFP
Dec 13, 2018 18:33 JST

NEC: Members Selected for the Research Program for the Development of a Quantum Annealing Machine Enabling High-Efficiency, High-Speed Processing
Dec 13, 2018 17:37 JST

Mitsubishi Motors to Relocate to a New Headquarters
Dec 13, 2018 17:20 JST

Production Milestone for Pratt & Whitney GTF PW1200G Engine at Mitsubishi Heavy Industries Aero Engines in Japan

Dec 13, 2018 10:28 JST

Mitsubishi Motors Secures Largest Fleet Sale of XPANDER to Garuda Indonesia

Dec 12, 2018 14:04 JST

Mitsubishi Corporation: Smart Meter Data Collection System 'Experiment' Launched in Hamamatsu
Dec 12, 2018 13:20 JST

GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics
Dec 12, 2018 10:06 JST

Showa Denko Announces Notice Regarding the Repurchase of Own Shares
Dec 11, 2018 14:00 JST

Showa Denko Forecasts Payment of Term-end Dividend
Dec 11, 2018 14:00 JST

More Latest Release >>